PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
41 hedge funds and large institutions have $1.05M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
9% less funds holding
Funds holding: 45 → 41 (-4)
67% less capital invested
Capital invested by funds: $3.13M → $1.05M (-$2.08M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$215K |
| 2 |
Renaissance Technologies
New York
|
+$164K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$75.7K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$46.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$66K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$14K |
| 3 |
Goldman Sachs
New York
|
-$10.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.08K |
| 5 |
HNB
Huntington National Bank
Columbus,
Ohio
|
-$5.89K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
27
Bank of New York Mellon
New York
| $1K | – | – | – |
|
|
BA
28
BlackRock Advisors
Wilmington,
Delaware
| $1K | – | – | – |
|
|
EC
29
Estate Counselors
Thiensville,
Wisconsin
| $1K | – | – | – |
|
|
FAAS
30
First Allied Advisory Services
San Diego,
California
| $1K | – | – | – |
|
|
PCM
31
Princeton Capital Management
Red Bank,
New Jersey
| $1K | – | – | – |
|
|
32
Citadel Advisors
Miami,
Florida
| – | -$66K | -178,100 | Closed |
|
|
33
Stifel Financial
St. Louis,
Missouri
| – | -$14K | -35,000 | Closed |
|
|
HNB
34
Huntington National Bank
Columbus,
Ohio
| – | -$5.89K | -27,000 | -99% |
|
|
TSS
35
Two Sigma Securities
New York
| – | -$4K | -11,466 | Closed |
|
36
Wells Fargo
San Francisco,
California
| – | +$981 | +4,500 | New |
|
PVCT Hedge Fund Activity: Q3 2016 in Review
41 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2016, worth a combined $1.05M — down 67% from $3.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of PVCT and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 9 added.
The largest buyer was Sabby Management, adding an estimated $215K. The largest seller was Citadel Advisors, exiting entirely with an estimated $66K sold.
- 41 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2016, down from 45 in Q2 2016.
- Funds reported $1.05M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2016, down 67% quarter-over-quarter.
- 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2016 and 3 closed out, a net change of -2 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2016 was Sabby Management, an estimated $215K added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2016 was Citadel Advisors, an estimated $66K sold.
Based on aggregated 13F filings for Q3 2016.